Basic Information
| LncRNA/CircRNA Name | FEZF-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR etc. |
| Sample | non-small cell lung cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | We found that lncRNA FEZF-AS1 was significantly up-regulated in tumour tissues when compared to the adjacent non-cancerous tissues (P=0.001), and it's high expression correlated with advanced stages (P=0.002) and Tumour Family History (P=0.029). Meanwhile, In 58 cases of NSCLC tissues the expression of lncRNA FEZF-AS1 was positively associated with that of FEZF1expression (r=0.8810, p=1.6575E-20). By GEPIA database analysis, we also found that the expression of lncRNA FEZF-AS1 and FEZF1 were significantly higher in tumour tissues than those of the adjacent non-cancerous tissues in 969 NSCLC patients (P<0.05), and lncRNA FEZF-AS1 was positively correlated with FEZF1 (r=0.90, P<0.001). These results suggest that lncRNA FEZF-AS1 relate to the progression of lung cancer patients and it may be a potential target for cancer therapy. |
| Pubmed ID | 29709443 |
| Year | 2018 |
| Title | Upregulation of LncRNA FEZF-AS1 is associated with advanced clinical stages and family history of cancer in patients with NSCLC. |
External Links
| Links for FEZF-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |